Clinical Trials 2010 - Frankfurt

North West Business Group29 - 30 September 2010, Frankfurt, Germany.
In the current environment where minimising cost and delivering ROI are critical themes within the pharma industry, improving your clinical trial infrastructure can ensure that time is not wasted and you are maximising your investments. Attend Clinical trials 2010, this two day meeting which is concise and packed with value, Presentations that will be case-study oriented, supplemented by panel discussions and network with leading practitioners to provide information to keep clinical trials goal-oriented, on-time and cost-effective. Take-aways will include presentations with information that can readily be adapted to clinical trial projects in your organization.The 2010 event is set to be a highlight in the clinical trial events calendar. What's more, it is widely accepted that there is nothing better than to learn from the experience of experts rather than trying to build that knowledge yourself.

The programme covers a wide range of topics including:

  • Clinical Trials in the 21st Century
  • Clinical trials in emerging economies: myth and reality
  • How to optimize the global patient recruitment process
  • Working with Academic Study Groups
  • How to attract and retain clinical trials in western countries
  • Outsourcing Innovative approaches
  • The effect of EU regulations on conducting clinical trials

Joins some of the experts like:

  • Astrazeneca, Clinical Research Director Europe
  • Grunenthal, Head of Clinical Operations
  • MDC, Senior PartnerProduct Specialist Clinical Business Intelligence Systems
  • Novartis, Chief Scientific Officer
  • Glaxo Smith Kline, Director Clinical Research
  • Actelion, Director, Global Clinical Development Affairs
  • Novartis, Head Clinical Operations
  • Lundbeck, Senior Specialist, Outsourcing
  • Janssen-Cilag, Head Clinical Trials
  • Sanofi-Aventis, Head of Clinical Research Unit
  • Bayer Health care, EDC Director
  • Pfizer, Associate Director Worldwide Regulatory Affairs & Quality Assurance
  • And many more...

Who should attend?
This conference is designed to attract key decision makers from the Pharmaceutical industry: Presidents, Managing Directors, Country Managers, General Managers, Vice Presidents, Regional Directors/ Heads, Directors, Department Heads, Managers.

For further information and registration, please visit:
http://nwbg.eu/all-events/clinical-trials-2010/

Most Popular Now

Novartis rises to second place in 2018 Access to M…

Novartis ranked second in the 2018 Access to Medicine Index (ATMi), up from 3rd place in 2016, in recognition of its long-standing efforts to improve worldwide access to ...

MSD is looking for a digital health solution to em…

MSD Lebanon is looking for an external partner to co-create a digital solution that helps oncologists to stay updated with relevant clinical content about cancer. The sol...

Lilly submits New Drug Application to the FDA for …

Eli Lilly and Company (NYSE: LLY) has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lasmiditan for the acute...

FDA approves new treatment for patients with acute…

The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for t...

Sanofi builds focus on rare blood disorders and ca…

Some of the most serious unmet patient needs today are in the field of hematology. Rare blood disorders and blood-related cancers continue to be a major focus of research...

New study reveals probiotics do not help children …

Probiotics are a multibillion-dollar industry with marketing claims of being an effective treatment for a multitude of ailments, including diarrhea. However, findings fro...

Merck and Pfizer provide update on avelumab in pla…

Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxor...

Bristol-Myers Squibb awards "Golden Tickets…

Bristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today anno...

U.S. FDA approves Larotrectinib, the first TRK inh…

The U.S. Food and Drug Administration (FDA) has approved larotrectinib, the first oral TRK inhibitor, under the brand name Vitrakvi®. The approval is for the treatment of...

Scorpion venom to shuttle drugs into the brain

The Peptides and Proteins lab at the Institute for Research in Biomedicine (IRB Barcelona) has published a paper in Chemical Communications describing the capacity of a s...

Abbott recommends rejection of below-market mini-T…

Abbott (NYSE: ABT) received notice of an unsolicited mini-tender offer by Baker Mills LLC (Baker Mills) to purchase up to 60,000 Abbott common shares, representing approx...

AstraZeneca to divest US Synagis rights to Sobi

AstraZeneca has agreed to sell US rights to Synagis (palivizumab) used for the prevention of serious lower respiratory tract infection (LRTI) caused by respiratory syncyt...